Efficacy and Safety of Intra-Arterial Thrombolysis in Central Retinal Artery Occlusion

医学 视网膜中央动脉阻塞 溶栓 眼科 视网膜 视力 灌注 闭塞 外科 心脏病学 心肌梗塞
作者
Seong Joon Ahn,Jae Min Kim,Jeong‐Ho Hong,Se Joon Woo,Jeeyun Ahn,Kyu Hyung Park,Moon‐Ku Han,Cheolkyu Jung
出处
期刊:Investigative Ophthalmology & Visual Science [Association for Research in Vision and Ophthalmology (ARVO)]
卷期号:54 (12): 7746-7746 被引量:68
标识
DOI:10.1167/iovs.13-12952
摘要

To investigate the efficacy and safety of intra-arterial thrombolysis (IAT) for acute central retinal artery occlusion (CRAO).Records from 101 CRAO patients treated with either IAT (n = 57) or standard treatment (ST; n = 44) were retrospectively reviewed. ST consisted of ocular massage and intraocular pressure-lowering agents. We used fundoscopic and angiographic findings to categorize CRAO as incomplete (diminished visual acuity [VA] with slight retinal edema, slight cherry-red spot), subtotal (severe VA reduction, cherry-red spot, distinct retinal edema), or total (massive edema, occluded perimacular arterioles, additional choroidal blood flow interruption). One-month and final best-corrected VA (BCVA) of the IAT group were compared with those of the ST group. Early (≤3-day) and final (1-month) reperfusion (improvement of retinal perfusion) rates were compared between groups. Subgroup analyses were performed according to CRAO stage.Overall, VA did not significantly differ between groups, but early reperfusion was greater in the IAT group (74.1% vs. 42.9%, P = 0.005). In incomplete CRAO, the IAT group exhibited greater visual improvement after 1 month (1.08 ± 0.21 vs. 0.23 ± 0.26 logarithmic values of the minimum angle of resolution [logMAR], P < 0.001) and at the final visit (1.08 ± 0.53 vs. 0.08 ± 0.57 logMAR, P < 0.001). However, in subtotal and total CRAO, no significant differences in visual outcomes were observed between groups. IAT resulted in clinically insignificant cerebral infarcts, detectable on brain imaging, in 8% of patients. Hemorrhagic transformation was not noted.The IAT treatment may provide early restoration of retinal perfusion and offer functional benefits in the management of incomplete CRAO.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
haochi发布了新的文献求助10
1秒前
1秒前
charry完成签到,获得积分10
3秒前
张宇鑫完成签到,获得积分10
4秒前
haochi完成签到,获得积分10
6秒前
sssaasa发布了新的文献求助10
7秒前
8秒前
10秒前
sube发布了新的文献求助10
11秒前
swordshine完成签到,获得积分0
13秒前
许小六完成签到 ,获得积分10
15秒前
乐天生完成签到,获得积分10
15秒前
15秒前
杏林靴子完成签到,获得积分10
17秒前
吱吱吱吱完成签到 ,获得积分10
18秒前
辛勤的泽洋完成签到 ,获得积分10
19秒前
collins发布了新的文献求助10
19秒前
乂氼完成签到 ,获得积分10
20秒前
韶冰蓝完成签到,获得积分10
23秒前
温柔樱桃完成签到 ,获得积分10
24秒前
害怕的听筠完成签到,获得积分10
27秒前
仁爱的觅夏完成签到,获得积分10
36秒前
爱睡觉的虾米完成签到 ,获得积分10
37秒前
Vista2023toFD完成签到,获得积分10
39秒前
chengxue完成签到,获得积分10
40秒前
微凉完成签到 ,获得积分10
42秒前
魔幻梦芝完成签到,获得积分10
44秒前
橙子发布了新的文献求助30
44秒前
ohh完成签到 ,获得积分10
50秒前
三脸茫然完成签到 ,获得积分0
52秒前
hhh完成签到 ,获得积分10
54秒前
空空道人完成签到 ,获得积分20
57秒前
cliff139完成签到,获得积分10
59秒前
共享精神应助高骏伟采纳,获得10
1分钟前
jinjing完成签到,获得积分10
1分钟前
ZZXX完成签到 ,获得积分10
1分钟前
笨笨的蓝天完成签到,获得积分10
1分钟前
1分钟前
隐形曼青应助collins采纳,获得30
1分钟前
稳重乌冬面完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
T/SNFSOC 0002—2025 独居石精矿碱法冶炼工艺技术标准 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6043109
求助须知:如何正确求助?哪些是违规求助? 7802498
关于积分的说明 16237910
捐赠科研通 5188612
什么是DOI,文献DOI怎么找? 2776637
邀请新用户注册赠送积分活动 1759682
关于科研通互助平台的介绍 1643238